Established in Singapore in 2003, Osteopore Limited focuses on engineering, manufacturing, and globally commercializing bioresorbable polymer implants. These advanced devices are utilized in neurosurgical, orthopedic, and maxillofacial operations throughout Singapore, Australia, and other international regions. The company's core innovation involves employing 3D printing with bioresorbable materials to create custom, micro-structured scaffolds specifically designed to foster bone regeneration. Its product portfolio includes Osteoplug, a resorbable implant for sealing trephination burr holes during neurosurgery, and Osteomesh, another resorbable implant used in craniofacial surgery to mend various fractures, including orbital floor injuries, and to fill surgical voids. Additionally, Osteopore has forged a collaborative partnership with Livingstone Health Holding Limited to jointly pioneer new products and applications for bone and tissue regeneration.
Subscribe to see OSTEOPORE LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OSTEOPORE LIMITED is a health care equipment & services company headquartered in Perth, Australia. It is publicly listed (OSX) with a market capitalisation of $891,359. Xcout tracks 5 named people at OSTEOPORE LIMITED, including Lim Yujing (Executive Director, Chief Executive Officer, Chief Technology Officer).
A few of OSTEOPORE LIMITED's closest competitors — see the full list of competitors and alternatives →
ReNerve Limited is a medical device company that develops products for the repair and replacement of damaged peripheral nerves. The company offers specialized solutions such as the NervAlign product range for nerve repair and the Empliq range of amniotic allografts and dermal matrices for wound and tissue management, primarily serving surgeons and clinicians.
Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across both clinical and pre-clinical settings in Australia, Germany, and other global regions. A notable offering is the FIVE2 (ViewnVivo) system, a compact confocal endomicroscope utilized for a broad range of research, including clinical, translational, and pre-clinical studies. Additionally, the company is actively developing the InVivage device, which is intended for use in cancer screening and surgical procedures. Established in 1994, Optiscan Imaging Limited maintains its headquarters in Mulgrave, Australia.
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle East, and Africa. Its portfolio of non-invasive, MRI-based diagnostic tools includes FerriScan, a system for quantifying liver iron concentration (LIC); FerriSmart, leveraging artificial intelligence (AI) for automated, real-time assessment of LIC; HepaFat-AI, an AI-driven solution for real-time, multi-metric liver fat quantification; CardiacT2, which provides dual analysis in conjunction with FerriScan to evaluate cardiac iron accumulation; HepaFat-Scan, a non-invasive MRI method for assessing liver fat within tissue; and LiverSmart, a comprehensive non-invasive MRI device integrating FerriSmart and HepaFat-AI for a unified report. The company further extends its offerings to include quantitative imaging measurements and Contract Research Organization (CRO) services, encompassing rigorous image analysis, imaging charter development, robust project and data management, proactive issue resolution, site tracking with clinical trial progress reports, and streamlined data flow coordination. They also provide comprehensive biomarker services, covering analysis of blood, urine, and protein analytes, alongside RNA, DNA, and genotyping. Their support for multinational and multicenter clinical trials extends to protocol development, subject inclusion/exclusion criteria assessment, dose modification strategies, new therapy safety profile evaluations, and establishing primary and secondary endpoints for drug efficacy. Additionally, they supply phantoms crucial for MRI machine calibration. Its client base includes clinicians, who utilize their solutions for managing human diseases, and pharmaceutical and therapeutic companies engaged in clinical research. Established in 1987, Resonance Health Limited maintains its headquarters in Burswood, Australia.
Headquartered in Melbourne, Australia, Vitasora Health Limited specializes in the research, development, and market introduction of medical devices across Australia and the United States. The company's portfolio also includes the creation of mobile health applications. Notably, the firm, previously known as Respiri Limited, officially rebranded as Vitasora Health Limited in April 2025.
Globally, Uscom Limited specializes in the creation, production, and distribution of non-intrusive medical instruments for assessing heart and lung health. Its product portfolio includes the USCOM 1A, a device utilizing Doppler ultrasound to non-invasively assess hemodynamic and cardiovascular performance. Also available is the BP+, a central blood pressure monitor employing supra-systolic oscillometry to gauge blood pressure and its waveforms both centrally (at the heart) and peripherally (in the arm). The company also produces the SpiroSonic, an ultrasound-based multi-path system for evaluating pulmonary function. Further expanding its offerings, Uscom presents the SpiroSonic AIR, a digital multipath ultrasonic spirometer featuring an integrated viral disinfection system capable of neutralizing pathogens like COVID and tuberculosis, alongside other respiratory equipment. Uscom's solutions are delivered to hospitals and various healthcare facilities via a broad network of distribution alliances. Established in 1999, the firm initially operated as Uscom Pty Limited before adopting the name Uscom Limited in October 2003. Its main corporate office is situated in Sydney, Australia.
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.